** Shares of Roivant Sciences gain 2.5% to $12.35 premarket
** Healthcare company Organon says it has agreed to buy skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion
** The deal gives OGN access to Dermavant's psoriasis cream, VTAMA, approved by the U.S. FDA in May 2022
** OGN to make an upfront payment of $175 million, as well as milestone payments of up to $950 million as part of the deal
** OGN expects to close the transaction in Q4 this year
** Up to last close, ROIV shares up 7.3% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。